Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

1. Why am I being given NUCALA? NUCALA contains the active ingredient mepolizumab. NUCALA is used to treat severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and ...

Nucala (mepolizumab) is a prescription drug used to treat a severe type of asthma and certain other inflammatory conditions. Nucala comes as an injection that you give under your skin. Nucala ...

GSK plc announced that the China National Medical Products Administration has accepted for review the new drug application for the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

The data suggest that Nucala could offer a meaningful benefit to those in need of additional treatments to reduce exacerbation risks. If approved, Nucala would be the first biologic with monthly ...

Submission based on data from MATINEE trial, which showed a significant and clinically meaningful reduction in rate of moderate/severe exacerbations with Nucala compared to placebo · Data ...

Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection.